Browse by title

You are looking at 1 - 10 of 147 items :

  • Competition and Antitrust Law x
  • Intellectual Property Law x
  • Chapters/Articles x
Clear All Modify Search
This content is available to you

Edited by Josef Drexl and Anselm Kamperman Sanders

You do not have access to this content

Edited by Paul Nihoul and Pieter Van Cleynenbreugel

This content is available to you

Edited by Paul Nihoul and Pieter Van Cleynenbreugel

This content is available to you

Edited by Paul Nihoul and Pieter Van Cleynenbreugel

This content is available to you

Edited by Paul Nihoul and Pieter Van Cleynenbreugel

You do not have access to this content

Helen Yu

Chapter 6 analyzes the contractual terms of the collaboration agreements collected from each of the four integrated drug discovery organizations with reference to the R & D Regulation and TTBER. Analysis of Article 101(3) exemptions will also be discussed with respect to whether they apply to the collaborative agreements should the agreements not qualify for exemption under the block exemptions.
You do not have access to this content

Helen Yu

Chapter 4 introduces the R & D Block Exemption Regulation and considers whether the R & D component of the collaboration agreement between integrated drug discovery organizations and industry falls within the purview of the R & D Regulation. It focuses on the concept of R & D poles and how they may restrict collaborative innovation in the drug discovery and development context.
You do not have access to this content

Helen Yu

Chapter 5 introduces the Technology Transfer Block Exemption Regulation (TTBER) and considers whether the licensing aspects of the collaboration agreement between integrated drug discovery organizations and industry falls within the purview of TTBER. It analyzes various contractual restrictions typically found in technology transfer agreements and how such restrictions are viewed from the perspective of competition policy.
You do not have access to this content

Helen Yu

Chapter 7 summarizes the legal implications of the integrated drug discovery model and discusses various concluding remarks, observations, and comments relating to integrated drug discovery in the larger innovation framework.
You do not have access to this content

Helen Yu

Chapter 3 introduces the intersection between competition policy and intellectual property rights in the context of collaborative research in the pharmaceutical sector and as it relates to the drug discovery and development process. It further explores the applicability of Article 101 to the collaboration agreement that governs the relationship between industry and integrated drug discovery organizations. The main focus of this chapter is to analyze and determine whether the collaboration agreements between industry and integrated drug discovery organizations fall within the purview of Article 101.